Drug Approval | April 22, 2024
Zydus launches Mirabegron ER Tablets in the US
Zydus is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg in the US market
Zydus is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg in the US market
Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of US$ 1,019 million in the US
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry
_256_384.png)
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Pemetrexed Injection is used as a drug, in the treatment of non-small cell lung cancer in combination with other chemotherapy agents
Natco Pharma intends to defend the matter accordingly
Thermo Fisher has equipped this Centre for Innovation with state-of-the-art platforms such as CellInsight CX7 LZR Pro High Content Screening Platform
Subscribe To Our Newsletter & Stay Updated
